CTOs on the Move


 
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.abcuro.com
  • 90 Bridge Street Suite 100
    Newton, AB USA 02458
  • Phone: 617.714.9759

Executives

Name Title Contact Details

Funding

Abcuro raised $42M on 01/07/2021

Similar Companies

Novara Tesija Michela and Priehs

Novara Tesija Michela and Priehs is a Southfield, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nano Mark

Nano Mark, Llc is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

180 Life Sciences

Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation

On Target Laboratories

Our illuminating molecules enhances the doctors ability to see disease tissue clearly improving their ability to treat cancer, autoimmune and other diseases.